Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches for Relapsed Refractory DLBCL episode artwork

EPISODE · Jun 20, 2024 · 50 MIN

Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches for Relapsed Refractory DLBCL

from Diffuse Large B-Cell Lymphoma CancerCare Connect Education Workshops

- Overview of Diffuse Large B-Cell Lymphoma (DLBCL), Including Staging and Grading, In the Context of COVID, Seasonal Flu and RSV - Current Standard of Care, New & Emerging Treatment Approaches - Treatment Options for Relapsed Refractory DLBCL, Including Bispecific Antibodies - Understanding How Bispecific Antibodies Work in the Treatment of Relapsed Refractory DLBCL - The Role of Clinical Trials: How Research Contributes to Treatment Options - Tips to Prevent & Manage Treatment Side Effects, Symptoms, Discomfort & Pain - Talking with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions for Our Panel of Experts

Episode metadata supplied by the publisher feed · Published Jun 20, 2024

Embed this episode

Ready to play

Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches for Relapsed Refractory DLBCL

0:00 50:57

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diffuse Large B-Cell Lymphoma CancerCare Connect Education Workshops?

This episode is 50 minutes long.

When was this Diffuse Large B-Cell Lymphoma CancerCare Connect Education Workshops episode published?

This episode was published on June 20, 2024.

Can I download this Diffuse Large B-Cell Lymphoma CancerCare Connect Education Workshops episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!